COYA · Insider Trading
Coya Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by COYA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-09 | Mark H Pavao | Director | A | +10,000 deriv. | — |
| 2026-01-26 | Fred Grossman | Chief Medical Officer | A | +140,041 deriv. | — |
| 2026-01-26 | David S Snyder | Chief Financial Officer | A | +140,041 deriv. | — |
| 2026-01-26 | Arun Swaminathan | Chief Executive Officer | A | +293,983 deriv. | — |
| 2026-01-26 | Howard Berman | Executive Chairman | A | +15,257 deriv. | — |
| 2026-01-06 | Dieter Weinand | Director | A | +10,000 deriv. | — |
| 2026-01-06 | Anabella Villalobos | Director | A | +10,000 deriv. | — |
| 2026-01-06 | Wilbur L Ross Jr | Director | A | +10,000 deriv. | — |
| 2026-01-06 | Dov A Md Goldstein | Director | A | +10,000 deriv. | — |
| 2026-01-06 | Ann Lee | Director | A | +10,000 deriv. | — |
| 2025-08-19 | Dov A Md Goldstein | Director | M | +17,557 | +$19.14K |
| 2025-02-25 | Ann Lee | Director | A | +5,000 deriv. | — |
| 2025-02-25 | Anabella Villalobos | Director | A | +5,000 deriv. | — |
| 2025-02-25 | Wilbur L Ross Jr | Director | A | +5,000 deriv. | — |
| 2025-02-25 | Dov A Md Goldstein | Director | A | +5,000 deriv. | — |
| 2025-02-25 | Dieter Weinand | Director | A | +5,000 deriv. | — |
| 2025-01-13 | Howard Berman | Director | A | +150,602 deriv. | — |
| 2025-01-13 | Fred Grossman | Chief Medical Officer | A | +140,562 deriv. | — |
| 2025-01-13 | Arun Swaminathan | Chief Executive Officer | A | +240,964 deriv. | — |
| 2025-01-13 | David S Snyder | Chief Financial Officer | A | +140,562 deriv. | — |
| 2025-01-03 | Ann Lee | Director | A | +5,000 deriv. | — |
| 2025-01-03 | Wilbur L Ross Jr | Director | A | +5,000 deriv. | — |
| 2025-01-03 | Dov A Md Goldstein | Director | A | +5,000 deriv. | — |
| 2025-01-03 | Dieter Weinand | Director | A | +5,000 deriv. | — |
| 2025-01-03 | Anabella Villalobos | Director | A | +5,000 deriv. | — |
| 2024-11-14 | David S Snyder | Chief Financial Officer | Buy | +1,800 | +$12.93K |
| 2024-11-13 | Arun Swaminathan | Chief Executive Officer | Buy | +5,000 | +$36.80K |
| 2024-11-12 | Arun Swaminathan | Chief Executive Officer | Buy | +5,000 | +$36.69K |
| 2024-11-12 | Fred Grossman | Chief Medical Officer | Buy | +2,710 | +$19.97K |
| 2024-06-05 | David S Snyder | Chief Financial Officer | A | +70,596 deriv. | — |
| 2024-06-05 | Howard Berman | Chief Executive Officer | A | +163,663 deriv. | — |
| 2024-06-05 | Fred Grossman | Chief Medical Officer | A | +70,596 deriv. | — |
| 2024-03-05 | Ann Lee | Director | Buy | +1,000 | +$3.62K |
| 2024-02-02 | David S Snyder | Chief Financial Officer | A | +81,819 deriv. | — |
| 2024-02-02 | Howard Berman | Chief Executive Officer | A | +189,680 deriv. | — |
| 2024-02-02 | Fred Grossman | Chief Medical Officer | A | +155,888 deriv. | — |
| 2024-01-19 | Dieter Weinand | Director | A | +5,000 deriv. | — |
| 2024-01-19 | Anabella Villalobos | Director | A | +5,000 deriv. | — |
| 2024-01-19 | Ann Lee | Director | A | +5,000 deriv. | — |
| 2024-01-19 | Hideki Garren | Director | A | +5,000 deriv. | — |
| 2024-01-19 | Dov A Md Goldstein | Director | A | +5,000 deriv. | — |
| 2024-01-04 | Wilbur L Ross Jr | Director | A | +10,000 deriv. | — |
| 2023-08-21 | Dieter Weinand | Director | A | +10,000 deriv. | — |
| 2023-07-19 | Fred Grossman | Chief Medical Officer | A | +74,069 deriv. | — |
| 2023-03-01 | David S Snyder | Chief Financial Officer | A | +115,000 deriv. | — |
| 2023-03-01 | Adrian Hepner | Chief Medical Officer | A | +115,000 deriv. | — |
| 2023-03-01 | Howard Berman | Chief Executive Officer | A | +165,000 deriv. | — |
| 2023-01-17 | Howard Berman | Chief Executive Officer | — | — | — |
| 2023-01-04 | Dov A Md Goldstein | Director | Buy | +10,000 | — |
| 2023-01-04 | Adrian Hepner | Chief Medical Officer | Buy | +10,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Howard Berman | Executive Chairman | 949,338 | $3.75M |
| Dov A Md Goldstein | Director | 27,557 | $108.85K |
| Ann Lee | Director | 27,479 | $108.54K |
| Anabella Villalobos | Director | 10,000 | $39.50K |
| Arun Swaminathan | Chief Executive Officer | 10,000 | $39.50K |
| David S Snyder | Chief Financial Officer | 8,800 | $34.76K |
| Fred Grossman | Chief Medical Officer | 2,710 | $10.70K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the COYA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.